Nitazoxanide

Nitazoxanide has been studied in 5 papers since 2021: none in people yet, 4 in animals; 2 in the past year. The research so far is in animals. The newest paper, Mar 27, 2026: “Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis”.

Intervention

5 papers study it14 findingsUpdated

PubChemChEBIMeSH

See all 5 papers on nitazoxanide

At a glance

The findings reach mice, none yet in people; independent labs found the same change in worms or flies. 4 independent labs in 3 countries; 7 trials, none about aging, 1 with no results posted.

None of its findings points the other way.

Worms or flies: replicated by independent labs. Cells and mice: a single group. Humans: nothing yet.
  • 4 independent labs in 3 countries
  • 7 trials, none about aging, 1 with no results posted
  • Funders: National Natural Science Foundation of China and 8 more
  • Animals3
  • Model organisms1
  • In silico1

What did studies of nitazoxanide find?

12

Studies of nitazoxanide measured 12 outcomes, among them lifespan, NFE2L2 and NLRP3.

Lifespan

upin worms2

2 studies
  1. Nitazoxanide extends lifespan in worms (NTZ treatment).

    “In C. elegans, NTZ treatment significantly extended both lifespan and healthspan”

    Model organismsNTZ treatment

    Anti-Aging Effects of Nitazoxanide in Caenorhabditis elegans and D-Galactose-Induced Accelerated Aging Mice

    International Journal of Drug Discovery and Pharmacology

  2. Nitazoxanide improves lifespan in worms (high glucose-induced lifespan shortening).

    “both nitazoxanide and tizoxanide improve high glucose-induced shortening of C. elegans lifespan”

    Model organismshigh glucose-induced lifespan shortening

    The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extend Caenorhabditis elegans lifespan and healthspan

    Acta pharmaceutica Sinica. B

  3. Nitazoxanide extends lifespan in worms (through Akt/AMPK/sir-2.1/daf-16 pathway).

    “both nitazoxanide and tizoxanide extend the lifespan and healthspan of Caenorhabditis elegans”

    Model organismsthrough Akt/AMPK/sir-2.1/daf-16 pathway

    The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extend Caenorhabditis elegans lifespan and healthspan

    Acta pharmaceutica Sinica. B

NFE2L2

upin rats1

1 study
  1. Nitazoxanide increases NFE2L2 in rats (acetic acid-induced colitis).

    “Conversely, both agents upregulated HO-1, Nrf2, SIRT1, Wnt, and AMPK levels.”

    Animalsacetic acid-induced colitiscolonn = 8

    Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis

    Naunyn-Schmiedeberg's archives of pharmacology

More on NFE2L2

NLRP3

downin rats1

1 study
  1. Nitazoxanide decreases NLRP3 in rats (acetic acid-induced colitis).

    “decreased expression of colonic mTOR, NLRP3, DKK1, IL-6, TNF-α, and STAT3”

    Animalsacetic acid-induced colitiscolonn = 8

    Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis

    Naunyn-Schmiedeberg's archives of pharmacology

More on NLRP3

Colitis

downin rats1

1 study
  1. Nitazoxanide decreases colitis in rats (acetic acid-induced colitis).

    “Both atorvastatin and nitazoxanide significantly attenuated colitis, as evidenced by reduced disease activity scores”

    Animalsacetic acid-induced colitiscolonn = 8

    Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis

    Naunyn-Schmiedeberg's archives of pharmacology

More on Colitis

Neurodegeneration

downin mice1

1 study
  1. Nitazoxanide protects against neurodegeneration in D-galactose-induced accelerated aging mice.

    “protected hippocampal neurons from degeneration”

    Animalsin D-galactose-induced accelerated aging micehippocampus

    Anti-Aging Effects of Nitazoxanide in Caenorhabditis elegans and D-Galactose-Induced Accelerated Aging Mice

    International Journal of Drug Discovery and Pharmacology

Cognitive function

upin mice1

1 study
  1. Nitazoxanide improves cognitive function in D-galactose-induced accelerated aging mice.

    “In the D-Gal mouse model, NTZ treatment ameliorated cognitive and physical decline”

    Animalsin D-galactose-induced accelerated aging mice

    Anti-Aging Effects of Nitazoxanide in Caenorhabditis elegans and D-Galactose-Induced Accelerated Aging Mice

    International Journal of Drug Discovery and Pharmacology

Locomotor activity

upin worms1

1 study
  1. Nitazoxanide improves locomotor activity in worms (NTZ treatment).

    “improved locomotor activity”

    Model organismsNTZ treatment

    Anti-Aging Effects of Nitazoxanide in Caenorhabditis elegans and D-Galactose-Induced Accelerated Aging Mice

    International Journal of Drug Discovery and Pharmacology

Healthspan

upin worms1

1 study
  1. Nitazoxanide improves healthspan in worms.

    “both nitazoxanide and tizoxanide extend the lifespan and healthspan of Caenorhabditis elegans”

    Model organisms

    The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extend Caenorhabditis elegans lifespan and healthspan

    Acta pharmaceutica Sinica. B

STAT3 phosphorylation

downin cells1

1 study
  1. Nitazoxanide decreases STAT3 phosphorylation in cells (receptor activator of NF-κB ligand-induced osteoclastogenesis).

    “osteoclastogenesis blockade elicited by NTZ resulted from inhibition of STAT3 phosphorylation”

    Cellsreceptor activator of NF-κB ligand-induced osteoclastogenesis

    Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis

    Frontiers in pharmacology

More on STAT3 phosphorylation

Bone loss

downin mice1

1 study
  1. Nitazoxanide decreases bone loss in mice (ovariectomized mice).

    “NTZ (100 mg/kg/d) administration markedly reduced ovariectomy-induced bone loss by suppressing osteoclast activity.”

    Animalsovariectomized micebone100 mg/kg/d3 months

    Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis

    Frontiers in pharmacology

All 12

Trial sponsors

Funding

1 grant since 2021

National Heart, Lung, and Blood Institute$256K

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 02 papers in 12 months